Abstract
The lack of consistent biomarkers for oral squamous cell carcinoma (OSCC) represents a major obstacle to individualizing treatment. Recently, interleukin 17F (IL-17F) has been implicated in the development of cancers in different organs. In OSCC, IL-17F levels were associated with a better prognosis and demonstrated predominantly antitumor effects, however, an association with disease pro…